Unknown

Dataset Information

0

Covid-19 and cardiovascular risk: Susceptibility to infection to SARS-CoV-2, severity and prognosis of Covid-19 and blockade of the renin-angiotensin-aldosterone system. An evidence-based viewpoint.


ABSTRACT: The presence of cardiovascular co-morbidities and the known effects of coronaviruses on the cardiovascular system have called attention to the potential implications for patients with cardiovascular risk factors. This evidence-based viewpoint will address two questions: (a) are individuals with underlying cardiovascular risk factors (e.g. high blood pressure or diabetes) or overt disease (e.g. coronary heart disease, heart failure, kidney disease) more likely to develop severe Covid-19 and to die than those without underlying conditions? (b) does the regular use of angiotensin-converting enzyme inhibitors (ACE-i) or angiotensin-receptor blockers (ARB) make patients more likely to get infected and to die of Covid-19? With a necessary cautionary note that the evidence around the links between Covid-19 and cardiovascular disease is accruing at a fast pace, to date we can conclude that: (a) the greater susceptibility of individuals with underlying cardiovascular conditions to develop more severe Covid-19 with higher mortality rate is likely to be confounded, in part, by age and the type of co-morbidities. Patients with heart failure or chronic kidney disease might show an excess risk; (b) neither ACE-i nor ARB are associated with greater risk of SARS-Cov2 infection, or severity or risk of death in patients with Covid-19. Patients on these drugs should not stop them, unless under strict medical supervision and with the addition of a suitable replacement medicine.

SUBMITTER: Cappuccio FP 

PROVIDER: S-EPMC7256508 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7509391 | BioStudies
2020-01-01 | S-EPMC7381180 | BioStudies
2020-01-01 | S-EPMC7239195 | BioStudies
2020-01-01 | S-EPMC7436520 | BioStudies
2021-01-01 | S-EPMC7368901 | BioStudies
2021-01-01 | S-EPMC7274611 | BioStudies
2020-01-01 | S-EPMC7184165 | BioStudies
2020-01-01 | S-EPMC7521934 | BioStudies
2016-01-01 | S-EPMC4783064 | BioStudies
2020-01-01 | S-EPMC7478439 | BioStudies